Arbutus Biopharma Logo
Tekmira Provides Corporate Update and Reports 2010 Audited Results
March 30, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 30, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2010 Audited Results
March 28, 2011 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 28, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Arbutus Biopharma Logo
Tekmira Sues Alnylam Pharmaceuticals for Repeated Misuse of Trade Secrets and Confidential Information
March 16, 2011 16:40 ET | Arbutus Biopharma Corporation
Complaint Also Alleges Unfair and Deceptive Trade Practices, Unjust Enrichment, Unfair Competition and False Advertising about Tekmira's Proprietary Lipid Nanoparticle (LNP) Technology Conference...
Arbutus Biopharma Logo
Tekmira Pharmaceuticals to Present at the ROTH 23rd Annual OC Growth Stock Conference
March 10, 2011 08:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Arbutus Biopharma Logo
Proof of RNAi in Man Strengthens Leadership Position of Tekmira's LNP Delivery Technology
January 10, 2011 08:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today provided...
Arbutus Biopharma Logo
Tekmira Initiates TKM-PLK1 Phase 1 Human Clinical Trial
December 22, 2010 08:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Dec. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Pharmaceuticals to Webcast Presentation at the Piper Jaffray Health Care Conference
November 24, 2010 08:30 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 24, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Arbutus Biopharma Logo
Tekmira Intellectual Property Portfolio Expands With Granting of Key Patents Covering LNP Manufacturing and Mitigation of siRNA Immune Stimulation
November 22, 2010 08:00 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Nov. 22, 2010 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TSX:TKM) (Nasdaq:TKMR), a leading developer of RNA interference (RNAi) therapeutics, announced today...